Using Illumina Infinium HumanMethylation 450K BeadChip to explore genome‑wide DNA methylation profiles in a human hepatocellular carcinoma cell line

Sun,Ning; Zhang,Jialin; Zhang,Chengshuo; Shi,Yue; Zhao,Bochao; Jiao,Ao; Chen,Baomin

doi:10.3892/mmr.2018.9441

Using Illumina Infinium HumanMethylation 450K BeadChip to explore genome‑wide DNA methylation profiles in a human hepatocellular carcinoma cell line

Authors:
- Ning Sun
- Jialin Zhang
- Chengshuo Zhang
- Yue Shi
- Bochao Zhao
- Ao Jiao
- Baomin Chen
View Affiliations

Affiliations: Department of Hepatobiliary and Transplantation Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: September 3, 2018 https://doi.org/10.3892/mmr.2018.9441
Pages: 4446-4456
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aberrant DNA methylation is the most common type of epigenetic alteration and is associated with many types of cancer. Although previous studies have provided a few novel DNA methylation markers in hepatocellular carcinoma (HCC), specific DNA methylation patterns and comparisons of the aberrant alterations in methylation between HCC and normal liver cell lines have not yet been reported. Therefore, in the present study the Illumina Infinium HumanMethylation 450K BeadChip was employed to identify the genome‑wide aberrant DNA methylation profiles of Huh7 and L02 cells. Following Bonferroni adjustment, 102,254 differentially methylated CpG sites (covering 26,511 genes) were detected between Huh7 and L02 cells. Of those CpG sites, 62,702 (61.3%) sites were hypermethylated (covering 12,665 genes) and 39,552 (38.7%) sites were hypomethylated (covering 13,846 genes). The results of the present study indicated that 40.3% of the CpG sites were in CpG island regions, 20.7% were in CpG shores and 8.8% were in shelf regions. A total of 57.3% hypermethylated CpG sites and 39.4% of the hypomethylated CpG sites had a |β‑Difference| ≥50%. Within the significant differentially methylated CpG sites, 490 genes were located within 598 differentially methylated regions. Gene Ontology enrichment analysis revealed that 2,107 differentially methylated genes were associated with ‘biological process’, 13,351 differentially methylated genes were associated with ‘molecular function’, and 18,041 differentially methylated genes were associated with ‘cellular component’. Kyoto Encyclopedia of Genes and Genomes pathway‑based analysis revealed 43 signaling pathways that were associated with 5,195 differentially methylated genes. These results demonstrated that aberrant DNA methylation may be a key and common event underlying the tumorigenesis of Huh7 cells. The present study also identified many subsets of hypo‑ or hyper‑methylated CpG sites, genes and signaling pathways, which have an importance in the occurrence and development of HCC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Zuo TT, Zheng RS, Zhang SW, Zeng HM and Chen WQ: Incidence and mortality of liver cancer in China in 2011. Chin J Cancer. 34:562015. View Article : Google Scholar : PubMed/NCBI
3	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
4	Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL and Inoue M: Hepatitis B and C virus infection and hepatocellular carcinoma in China: A review of epidemiology and control measures. J Epidemiol. 21:401–416. 2011. View Article : Google Scholar : PubMed/NCBI
5	Panayiotidis MI: Cancer epigenetics as biomarkers of clinical significance. Cancer Lett. 342:168–169. 2014. View Article : Google Scholar : PubMed/NCBI
6	Udali S, Guarini P, Moruzzi S, Ruzzenente A, Tammen SA, Guglielmi A, Conci S, Pattini P, Olivieri O, Corrocher R, et al: Global DNA methylation and hydroxymethylation differ in hepatocellular carcinoma and cholangiocarcinoma and relate to survival rate. Hepatology. 62:496–504. 2015. View Article : Google Scholar : PubMed/NCBI
7	Jones PA and Takai D: The role of DNA methylation in mammalian epigenetics. Science. 293:1068–1070. 2001. View Article : Google Scholar : PubMed/NCBI
8	Esteller M: Epigenetics in cancer. N Engl J Med. 358:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
9	Jain S, Xie L, Boldbaatar B, Lin SY, Hamilton JP, Meltzer SJ, Chen SH, Hu CT, Block TM, Song W and Su YH: Differential methylation of the promoter and first exon of the RASSF1A gene in hepatocarcinogenesis. Hepatol Res. 45:110–123. 2015. View Article : Google Scholar
10	Hinrichsen I, Kemp M, Peveling-Oberhag J, Passmann S, Plotz G, Zeuzem S and Brieger A: Promoter methylation of MLH1, PMS2, MSH2 and p16 is a phenomenon of advanced-stage HCCs. PLoS One. 9:e844532014. View Article : Google Scholar : PubMed/NCBI
11	Xu B, Nie Y, Liu X, Feng S, Yang Z, Wang Z, Zheng Q and Luo X: Quantitative analysis of APC promoter methylation in hepatocellular carcinoma and its prognostic implications. Oncol Lett. 7:1683–1688. 2014. View Article : Google Scholar : PubMed/NCBI
12	Jain S, Chen S, Chang KC, Lin YJ, Hu CT, Boldbaatar B, Hamilton JP, Lin SY, Chang TT, Chen SH, et al: Impact of the location of CpG methylation within the GSTP1 gene on its specificity as a DNA marker for hepatocellular carcinoma. PLoS One. 7:e357892012. View Article : Google Scholar : PubMed/NCBI
13	Qu Z, Jiang Y, Li H, Yu DC and Ding YT: Detecting abnormal methylation of tumor suppressor genes GSTP1, P16, RIZ1, and RASSF1A in hepatocellular carcinoma and its clinical significance. Oncol Lett. 10:2553–2558. 2015. View Article : Google Scholar : PubMed/NCBI
14	Shen J, Wang S, Zhang YJ, Wu HC, Kibriya MG, Jasmine F, Ahsan H, Wu DP, Siegel AB, Remotti H and Santella RM: Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using Infinium HumanMethylation 450 BeadChips. Epigenetics. 8:34–43. 2013. View Article : Google Scholar : PubMed/NCBI
15	Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, Delano D, Zhang L, Schroth GP, Gunderson KL, et al: High density DNA methylation array with single CpG site resolution. Genomics. 98:288–295. 2011. View Article : Google Scholar : PubMed/NCBI
16	Esteller M: Epigenetic gene silencing in cancer: The DNA hypermethylome. Hum Mol Genet. 16:R50–R59. 2007. View Article : Google Scholar : PubMed/NCBI
17	Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 349:2042–2054. 2003. View Article : Google Scholar : PubMed/NCBI
18	Yates DR, Rehman I, Meuth M, Cross SS, Hamdy FC and Catto JW: Methylational urinalysis: A prospective study of bladder cancer patients and age stratified benign controls. Oncogene. 25:1984–1988. 2006. View Article : Google Scholar : PubMed/NCBI
19	Dudziec E, Miah S, Choudhry HM, Owen HC, Blizard S, Glover M, Hamdy FC and Catto JW: Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer. Clin Cancer Res. 17:1287–1296. 2011. View Article : Google Scholar : PubMed/NCBI
20	Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, Webster M, et al: The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 41:178–186. 2009. View Article : Google Scholar : PubMed/NCBI
21	Nishida N, Kudo M, Nagasaka T, Ikai I and Goel A: Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology. 56:994–1003. 2012. View Article : Google Scholar : PubMed/NCBI
22	Shen J, Wang S, Zhang YJ, Kappil M, Wu HC, Kibriya MG, Wang Q, Jasmine F, Ahsan H, Lee PH, et al: Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology. 55:1799–1808. 2012. View Article : Google Scholar : PubMed/NCBI
23	Udali S, Guarini P, Ruzzenente A, Ferrarini A, Guglielmi A, Lotto V, Tononi P, Pattini P, Moruzzi S, Campagnaro T, et al: DNA methylation and gene expression profiles show novel regulatory pathways in hepatocellular carcinoma. Clin Epigenetics. 7:432015. View Article : Google Scholar : PubMed/NCBI
24	Gao W, Kondo Y, Shen L, Shimizu Y, Sano T, Yamao K, Natsume A, Goto Y, Ito M, Murakami H, et al: Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis. 29:1901–1910. 2008. View Article : Google Scholar : PubMed/NCBI
25	Shin SH, Kim BH, Jang JJ, Suh KS and Kang GH: Identification of novel methylation markers in hepatocellular carcinoma using a methylation array. J Korean Med Sci. 25:1152–1159. 2010. View Article : Google Scholar : PubMed/NCBI
26	Ammerpohl O, Pratschke J, Schafmayer C, et al: Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma. Int J Cancer. 130:1319–1328. 2012. View Article : Google Scholar : PubMed/NCBI
27	Kohles N, Nagel D, Jüngst D, Durner J, Stieber P and Holdenrieder S: Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol. 33:33–40. 2012. View Article : Google Scholar : PubMed/NCBI
28	Doi A, Park IH, Wen B, Murakami P, Aryee MJ, Irizarry R, Herb B, Ladd-Acosta C, Rho J, Loewer S, et al: Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet. 41:1350–1353. 2009. View Article : Google Scholar : PubMed/NCBI
29	Ogoshi K, Hashimoto S, Nakatani Y, Qu W, Oshima K, Tokunaga K, Sugano S, Hattori M, Morishita S and Matsushima K: Genome-wide profiling of DNA methylation in human cancer cells. Genomics. 98:280–287. 2011. View Article : Google Scholar : PubMed/NCBI
30	Rakyan VK, Down TA, Balding DJ and Beck S: Epigenome-wide association studies for common human diseases. Nat Rev Genet. 12:529–541. 2011. View Article : Google Scholar : PubMed/NCBI
31	Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL and Schübeler D: Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet. 37:853–862. 2005. View Article : Google Scholar : PubMed/NCBI
32	Calvisi DF, Pascale RM and Feo F: Dissection of signal transduction pathways as a tool for the development of targeted therapies of hepatocellular carcinoma. Rev Recent Clin Trials. 2:217–236. 2007. View Article : Google Scholar : PubMed/NCBI
33	Kuo KK, Jian SF, Li YJ, Wan SW, Weng CC, Fang K, Wu DC and Cheng KH: Epigenetic inactivation of transforming growth factor-beta1 target gene HEYL, a novel tumor suppressor, is involved in the P53-induced apoptotic pathway in hepatocellular carcinoma. Hepatol Res. 45:782–793. 2015. View Article : Google Scholar : PubMed/NCBI
34	Umer M, Qureshi SA, Hashmi ZY, Raza A, Ahmad J, Rahman M and Iqbal M: Promoter hypermethylation of Wnt pathway inhibitors in hepatitis C virus-induced multistep hepatocarcinogenesis. Virol J. 11:1172014. View Article : Google Scholar : PubMed/NCBI
35	Ding SL, Yang ZW, Wang J, Zhang XL, Chen XM and Lu FM: Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 21:6317–6328. 2015. View Article : Google Scholar : PubMed/NCBI
36	Stefanska B, Cheishvili D, Suderman M, Arakelian A, Huang J, Hallett M, Han ZG, Al-Mahtab M, Akbar SM, Khan WA, et al: Genome-wide study of hypomethylated and induced genes in patients with liver cancer unravels novel anticancer targets. Clin Cancer Res. 20:3118–3132. 2014. View Article : Google Scholar : PubMed/NCBI
37	Yan W, Herman JG and Guo M: Epigenome-based personalized medicine in human cancer. Epigenomics. 8:119–133. 2016. View Article : Google Scholar : PubMed/NCBI
38	Ghoshal K and Bai S: DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc). 43:395–422. 2007. View Article : Google Scholar : PubMed/NCBI
39	Yoo CB, Jeong S, Egger G, Liang G, Phiasivongsa P, Tang C, Redkar S and Jones PA: Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 67:6400–6408. 2007. View Article : Google Scholar : PubMed/NCBI
40	Datta J, Ghoshal K, Denny WA, Gamage SA, Brooke DG, Phiasivongsa P, Redkar S and Jacob ST: A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res. 69:4277–4285. 2009. View Article : Google Scholar : PubMed/NCBI
41	Gros C, Fleury L, Nahoum V, Faux C, Valente S, Labella D, Cantagrel F, Rilova E, Bouhlel MA, David-Cordonnier MH, et al: New insights on the mechanism of quinoline-based DNA Methyltransferase inhibitors. J Biol Chem. 290:6293–6302. 2015. View Article : Google Scholar : PubMed/NCBI